PARP inhibitors (PARPi) have revolutionized treatment for cancers characterized by deficiencies in DNA repair mechanisms, particularly those involving mutations to the homologous recombination repair proteins, BRCA1 and BRCA2 (1). Here, PARP1 is linked to cancer.